Shots: The EUA submission is based on P-III ENSEMBLE trial assessing the safety and efficacy of the COVID-19 vaccine in protecting adults aged ≥18yrs. against both mod. and sev. COVID-19 disease with assessment of efficacy as of day 14 and as of day 28 as co-1EPs The study demonstrated that single-dose vaccine met all 1EPs […]Read More
Shots: The first healthy volunteer has been dosed in a P-I study of GRAd-COV2 against COVID-19 which is conducted by the Lazzaro Spallanzani National Institute for Infectious Diseases under the sponsorship of ReiThera The P-I study will evaluate the safety & immunogenicity of GRAd-COV2 in 90 healthy volunteers divided equally into two age cohorts: 18-55yrs. […]Read More
Shots: Valneva to receive $308M in cash including $130M up front, $35M as development milestones and $143M as early commercialization milestones and will fund 30% of all development costs through completion of the development program while in exchange Pfizer will pay Valneva royalties starting at 19% Pfizer will lead the late stage development of VLA15 […]Read More
Shots The company has commenced P-I clinical study assessing its vaccine candidate vs PBO in 144 healthy adults, aged 18-59yrs, with two different dosages of the vaccine candidate, conducted in Jiangsu Province The study evaluates the safety, tolerance, and preliminary immunogenicity of Sinovac’s SARS-CoV-2 vaccine under which two-thirds of the volunteers will be vaccinated with […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
